dr. verstovsek on limitations of the current treatment landscape of myelofibrosis
Published 4 years ago • 230 plays • Length 2:16Download video MP4
Download video MP3
Similar videos
-
2:10
dr. verstovsek on accelerated phase myelofibrosis
-
1:48
dr. verstovsek on examining cpi-0610 in myelofibrosis
-
1:21
dr. verstovsek discusses immunotherapy in myelofibrosis
-
1:45
dr. verstovsek on the manifest trial with cpi-0610 in myelofibrosis
-
1:48
dr. scherber on the treatment of myelofibrosis
-
1:23:15
drs.verstovsek & mesa discuss latest myelofibrosis updates from #soho2021: https://bit.ly/3hfp1kc
-
25:39
for myelofibrosis patients: latest on treatments from top doctor | dr. srdan verstovsek, md anderson
-
6:11
primary myelofibrosis disease state
-
1:45
evaluating cpi-0610 as treatment of patients with myelofibrosis
-
24:31
managing myelofibrosis in 2021 - dr. srdan verstovsek
-
1:19
dr. srdan verstovsek on jak2 inhibitors as a treatment for myelofibrosis
-
0:49
dr. mims on the current challenges with myelofibrosis
-
5:54
treating intermediate/high-risk primary myelofibrosis
-
3:51
new therapies for myelofibrosis
-
3:20
promising et, pv & myelofibrosis therapies in development
-
1:02
myelofibrosis: unmet needs
-
5:58
mutations, diagnosis, and prognosis in myelofibrosis
-
1:29
serge verstovsek, md on myelofibrosis
-
5:17
when to initiate therapy in myelofibrosis